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Aldosterone antagonists: Silver 
bullet or just sodium excretion and 
potassium retention?
U Wenzel1
ACE inhibitors or AT1 antagonists are powerful therapeutic strategies 
to slow the progression of renal disease. However, they provide only 
imperfect protection since they cannot always prevent end-stage renal 
failure. Innovative approaches are needed to keep patients with chronic 
kidney disease off dialysis. Blockade of the aldosterone pathway may 
prove to be such a beneficial therapeutic concept.
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Introduction
The prevalence of end-stage renal dis-
ease is rising at an alarming rate, and the 
increasing number of patients with end-
stage renal disease is one of the major 
challenges in today’s nephrology practices 
worldwide. Hypertension and proteinuria 
are the most important risk factors for the 
progression of renal disease. Angiotensin-
converting enzyme (ACE) inhibition and 
angiotensin receptor type 1 (AT1) antago-
nism are beneficial in lowering blood 
pressure and reducing proteinuria. Regres-
sion of glomerular injury by blockade of 
the renin–angiotensin system has been 
shown in various experimental animal 
models of renal disease. Th erefore it may 
even improve long-term outcome by facili-
tating the remodeling and restoration of 
the normal glomerular architecture. How-
ever, less is known about the regression of 
tubulointerstitial injury by blockade of the 
renin–angiotensin system. Whether ACE 
inhibition results in the breakdown and 
removal of interstitial collagen and thereby 
potentially improves long-term functional 
recovery is currently undetermined.
Kramer and colleagues1 (this issue) 
examined the eff ect of combining the 
ACE inhibitor lisinopril and the aldos-
terone antagonist spironolactone in a rat 
model of adriamycin-induced nephrosis 
and kidney damage. Tubular injury was 
quantifi ed by markers such as osteopon-
tin and kidney injury molecule-1 (Kim-
1). In addition, focal glomerulosclerosis, 
prefi brotic lesions, and interstitial fi bro-
sis were quantifi ed. Th e authors found 
a remarkable reduction of glomerulo-
sclerosis and markers of tubular and 
interstitial damage in the combination 
group.1 Importantly, Kramer et al.1 used 
a “curative” model design, starting their 
therapeutic intervention at a time when 
proteinuria was fully developed and 
thereby resembled more closely the clin-
ical situation in which patients usually 
present with the nephrotic syndrome.
New biology of aldosterone
It was originally thought that aldosterone 
was a hormone solely released from the 
adrenal cortex; according to this doctrine, 
it only aff ected the kidney by regulating 
sodium reabsorption and potassium 
and proton secretion. In recent years, 
this simplistic concept has changed, and 
we now have a better appreciation of the 
multitude of eff ects aldosterone can have 
not only on tubular epithelial cells but 
also on endothelial dysfunction, infl am-
mation, protein excretion, and fi brosis.2,3 
We now know that aldosterone is made 
in various organs, including the brain, 
vessels, and the myocardium, and that 
many tissues also express mineralocorti-
coid receptors. Aldosterone probably acts 
in a paracrine fashion in many organs. 
Blockade of the renin–angiotensin sys-
tem by ACE inhibitors or AT1 antago-
nists should decrease aldosterone levels 
and ameliorate the eff ects of aldoster-
one.2 Indeed, ACE inhibition produces 
an acute fall in plasma aldosterone. Th is 
eff ect, however, is oft en only transient 
and followed by a progressive rise in 
aldosterone levels that ultimately, with 
long-term ACE inhibition, can reach 
normal or even elevated readings. Th is 
phenomenon has been called “aldoster-
one escape.” Th e precise mechanisms by 
which aldosterone levels rise during ACE 
inhibition are unknown. ACE inhibition 
increases serum potassium levels, and, 
as potassium is a powerful secretagogue 
stimulus for aldosterone, this may be a 
major reason for aldosterone escape in 
some patients.2
Aldosterone and hypertension
Spironolactone and eplerenone are ster-
oid analogues with structural similarity 
to aldosterone and thereby function as 
competitive antagonists. Eplerenone has 
less antiandrogenic and antiprogesteronic 
eff ects than spironolactone. Several tri-
als have shown that spironolactone and 
eplerenone reduce blood pressure eff ec-
tively. Recent clinical studies indicate that 
aldosterone antagonists provide especially 
significant additional blood pressure 
reduction when added to treatment regi-
mens of patients with therapy-resistant 
hypertension.4 Th is does not mean that 
aldosterone antagonists are fi rst-line anti-
hypertensive drugs. However, they may 
be useful add-on antihypertensive drugs, 
producing a fairly predictable additional 
pressure-lowering eff ect in all patients. An 
issue left  largely unresolved by the stud-
ies in patients with arterial hypertension 
is whether the benefi t of spironolactone 
lies in its diuretic eff ect or in its ability to 
modify the non-volume-mediated eff ects 
of aldosterone. Th erefore, it is very inter-
esting to compare spironolactone with 
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the potassium-sparing diuretic amiloride 
or triamterene. Amiloride and triamteren 
indirectly inhibit the eff ect of aldosterone 
on basolateral Na-K-ATPase by block-
ing luminal epithelial sodium channels 
in the distal collecting duct, eff ectively 
reducing the intracellular substrate for 
the sodium pump. Th e epithelial sodium 
channel is upregulated by aldosterone, 
such that amiloride and triamteren func-
tion as indirect aldosterone antagonists, 
as shown in Figure 1. If actions outside 
of the epithelial sodium channel activ-
ity were provoked by aldosterone, then 
one would predict that the aldosterone 
receptor blockers would be more widely 
eff ective than amiloride or triamteren. 
However, use of amiloride mimics quite 
successfully the eff ects of spironolactone 
in patients with resistant hypertension, 
raising doubts that — at least in therapy-
resistant hypertension — the benefi cial 
eff ects of spironolactone are due to non-
diuretic eff ects.5
Aldosterone and proteinuria
More than ten years ago, Greene et al.6 
demonstrated that aldosterone con-
tributes to proteinuria and glomerular 
injury in the remnant kidney model. 
Proteinuria is an important risk factor 
for the progression of chronic kidney 
disease. Several studies have shown 
that in proteinuric patients the addition 
of spironolactone to an ACE inhibitor 
leads to further reduction of proteinuria 
(reviewed by Pondo and Hostetter3). In 
some studies the addition of the aldos-
terone antagonists to an ACE inhibitor 
induced even more profound reduction 
of proteinuria than the addition of an 
AT1 antagonist.
7 Unfortunately, addi-
tion of spironolactone also decreased 
blood pressure in some studies, making 
it diffi  cult to judge whether the benefi cial 
eff ects were due to blood pressure reduc-
tion or specifi c antiproteinuric eff ects of 
the aldosterone antagonists. However, 
no data are available on whether the 
addition of an aldosterone antagonist 
can inhibit the long-term progression of 
renal diseases to end-stage failure. Stud-
ies with fi rm end points such as doubling 
of creatinine or end-stage renal disease 
would be highly desirable. Promising 
data have been recently published by 
Bianchi et al.8 Th ey evaluated the eff ect 
of 25 mg spironolactone on proteinuria 
and estimated glomerular fi ltration rate 
(GFR) in patients with chronic kidney 
disease already treated with ACE inhibi-
tors and/or AT1 antagonists. Aft er 1 year 
of therapy, proteinuria decreased from 
2.1 to 0.89 g per g creatinine in patients 
treated with spironolactone but did not 
change in control patients. In addition, 
by the end of 1 year, the monthly rate of 
decrease in estimated GFR was lower in 
patients treated with spironolactone than 
in controls.8 Th is is the fi rst evidence that 
an aldosterone antagonist in addition 
to ACE inhibitors and AT1 antagonists 
may be useful in halting progression 
of chronic kidney disease. However, 
spironolactone was associated with a 
signifi cant increase in serum potassium 
levels. Th e potential threat of hyperkale-
mia requires further clinical studies and 
experience to test the safety of this treat-
ment. Th e same group reported recently 
that patients with a GFR less than 60 ml 
per min are more likely than those with 
a GFR greater than 60 ml per min to 
develop hyperkalemia.
More than excreting sodium and retain-
ing potassium?
Like the treatment of resistant hyperten-
sion, another issue left  largely unresolved 
by these results is whether the benefi t 
of spironolactone lies simply in its diu-
retic eff ect. Subtle natriuretic eff ects of 
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Figure 1 | Aldosterone and sodium retention. Aldosterone binds to the aldosterone receptor 
in the principal cell of the collecting duct and stimulates sodium reabsorption across the luminal 
membrane through epithelial sodium channels by increasing the number of open sodium 
channels and increasing the number of Na-K-ATPase pumps. Reabsorbed sodium is pumped out 
of the cell by the Na-K-ATPase pump in the basolateral (peritubular) membrane. Spironolactone 
and eplerenone act by competing with aldosterone. Triamteren and amiloride function as indirect 
aldosterone antagonists by closing the epithelial sodium channels. (Adapted from refs. 11 and 12.)
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spironolactone may have increased the 
effi  cacy of the ACE inhibitor to reduce 
glomerulosclerosis and markers of tubu-
lar and interstitial damage in the study 
of Kramer et al.1 Th erefore, it is of great 
interest that Kramer et al.1 compared 
spironolactone with amiloride in their 
model with chronic adriamycin neph-
ropathy to control for the effects of 
spironolactone on volume and potassium 
status. In their hands, addition of amilo-
ride to the ACE inhibitor did not mimic 
the benefi cial eff ects of spironolactone; 
this clearly indicates that the benefi cial 
eff ect of spironolactone was mediated by 
non-diuretic eff ects of the drug.
Th is is in line with previous work by 
Hamming et al.9 showing that treat-
ment of rats with adriamycin nephrosis 
with an ACE inhibitor during dietary 
sodium restriction had benefi cial eff ects 
on glomerular injury and decreased 
proteinuria but induced tubulointer-
stitial abnormalities and an increase in 
the total medial area of aff erent arteri-
oles. Th ese arterioles stained positive for 
renin. A direct profi brotic role for renin 
has been postulated independent of its 
ability to generate angiotensin.10 Th ese 
data are distressing, as treatment with 
the ACE inhibitor induced renal fi brosis 
in spite of reduction of proteinuria and 
blood pressure, that is, an improvement 
of the established clinical criteria for a 
good response to therapy. In humans, it 
is usually not feasible to monitor renal 
structural damage during therapy.9
Further studies are needed to explore 
the effect of different diuretics on the 
tubulointerstitium and dissect the 
underlying mechanisms by which vol-
ume depletion infl uences the eff ect of 
ACE inhibition on glomerular and tubu-
lointerstitial injury.
Conclusion
Aldosterone blockade reduces blood 
pressure in virtually all patients with 
hypertension, and aldosterone antago-
nists are useful second- or third-line 
antihypertensive drugs. In addition, 
aldosterone blockade in combination 
with an ACE inhibitor or an AT1 antago-
nist reduces glomerular and tubulointer-
stitial injury in models of renal disease, 
as shown by Kramer et al.1 In proteinu-
ric patients, addition of an aldosterone 
antagonist reduces proteinuria. Initial 
encouraging pilot data are available sug-
gesting that this may translate into pres-
ervation of the GFR in the longer term. 
More clinical studies are warranted to 
address more defi nitively the safety and 
the effi  cacy of aldosterone antagonists 
in advanced chronic kidney disease. 
And fi nally, coming back to the observa-
tion by Kramer et al.1 and Hamming et 
al.,9  further work is needed to shed light 
on the precise mechanisms underlying 
eff ects of volume depletion on the tubu-
lointerstitium during ACE inhibition.
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Control of hyperphosphatemia 
beyond phosphate
P Evenepoel1
Hyperphosphatemia is a prevalent condition in the dialysis population 
and is associated with bad outcome. Block et al. present data 
from a post hoc analysis indicating that sevelamer, a noncalcium-
containing phosphate binder , may confer a survival benefit in 
incident hyperphosphatemic hemodialysis patients. This is the first 
intervention study in the field of mineral metabolism showing a 
beneficial effect on a hard end point.  
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Patients with chronic kidney disease 
(CKD) are at increased risk for car-
diovascular morbidity and mortality.1 
At present, the data support excessive 
atherosclerosis in CKD, and atheroscle-
rotic lesions in CKD patients are more 
likely to be severely calcifi ed than those 
in the general population.2 Furthermore, 
there is increasing stiff ening of larger 
elastic arteries in CKD, with increased 
calcification.3 At least in non-uremic 
individuals, both the extent and the pro-
gression of cardiovascular calcifi cation 
have been associated with a substantial 
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